Natera, Inc. is a biotechnology company that specializes in genetic testing and diagnostics. The company operates in the healthcare sector, focusing on providing advanced testing solutions for various medical needs. Natera serves a diverse range of clients, including cancer patients, transplant patients, and individuals planning families or assessing hereditary health risks.

Natera's core technology revolves around cell-free DNA (cfDNA) testing, which involves analyzing small fragments of DNA circulating in the blood. This technology is used to detect molecular residual disease (MRD) in cancer patients, helping guide treatment decisions by identifying minimal traces of cancer that might remain after treatment. The company also offers the Signatera test, a custom-built ctDNA (circulating tumor DNA) test for cancer patients, which can be accessed remotely through their GI Expanded Access Program.

In addition to oncology, Natera provides testing solutions for organ health, particularly for transplant patients. Their cfDNA testing helps assess the health of transplanted organs, ensuring early detection of potential issues. For women's health, Natera offers a range of tests that support family planning, prenatal screening, and hereditary cancer risk assessment. One of their notable products, Panorama NIPT (Non-Invasive Prenatal Testing), has achieved a significant milestone of 2 million tests conducted.

Natera's business model is based on providing these specialized testing services to healthcare providers, hospitals, and directly to patients. They generate revenue through the sale of their testing kits and services, which are often reimbursed by insurance companies. The company also offers genetic counseling services, allowing patients to connect with counselors remotely for personalized guidance.

Keywords: genetic testing, cfDNA, cancer detection, MRD, ctDNA, prenatal screening, transplant health, hereditary cancer, biotechnology, healthcare diagnostics.